Related Experiment Video
Updated: Apr 3, 2026

Traditional Trail Making Test Modified into Brand-new Assessment Tools: Digital and Walking Trail Making Test
Published on: November 23, 2019
An overview of the design and conduct of the BATTLE trials
1Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Abstract:
Our increasing knowledge of biomedicine and genomics for human malignancies has placed us within reach of achieving personalized cancer medicine. The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE)-1 trial was the first completed, prospective biopsy-mandated, biomarker-based, adaptive randomized clinical trial for patients with advanced non-small cell lung cancer (NSCLC). The ongoing BATTLE-2 trial continues to search for effective targeted therapies by further refining the clinical trial design. The BATTLE program has demonstrated the feasibility and promise of novel biomarker-based clinical trial platforms, which has moved us one step closer to personalized medicine. In this paper, we describe the design and conduct of the BATTLE trials, summarize the main findings, and report the experiences and lessons learned from our pursuit of developing targeted therapies in cancer.
Insights
The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trials show that biomarker-based adaptive trials are feasible for developing personalized lung cancer therapies. These trials advance targeted treatment strategies for non-small cell lung cancer.
Area of Science:
- Biomedicine
- Genomics
- Oncology
Background:
- Advances in biomedicine and genomics are enabling personalized cancer medicine.
- Lung cancer treatment has historically relied on broad approaches, necessitating more targeted strategies.
Purpose of the Study:
- To describe the design and conduct of the BATTLE-1 and BATTLE-2 trials.
- To summarize key findings and lessons learned from these biomarker-based adaptive trials.
- To evaluate the feasibility and promise of novel clinical trial platforms for targeted cancer therapy.
Main Methods:
- Prospective, biopsy-mandated, biomarker-based, adaptive randomized clinical trials.
- Focus on patients with advanced non-small cell lung cancer (NSCLC).
- Refinement of clinical trial design in the ongoing BATTLE-2 trial.
Main Results:
- The BATTLE program demonstrated the feasibility of its adaptive trial design.
- Biomarker-based approaches show promise for identifying effective targeted therapies.
- The trials represent a step towards personalized medicine in lung cancer treatment.
Conclusions:
- Biomarker-driven adaptive clinical trials are effective for advancing targeted lung cancer therapy.
- The BATTLE program provides a successful model for personalized cancer medicine development.
- Further refinement of trial design can enhance the discovery of novel targeted therapies.
More Related Videos
Related Concept Videos
Blinding
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Clinical Trials
There are four phases in a clinical trial. A phase one...
Robbers Cave
Group Design
Crossover Experiments
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.

